Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC By Ogkologos - April 15, 2025 197 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... July 22, 2020 The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... March 22, 2022 Load more HOT NEWS Repurposing radiotherapy drugs could give immunotherapy a boost EMA Recommends Granting a Marketing Authorisation for Generic Sorafenib Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... Philanthropist Simon Collins: “I realised I could make a difference by...
